FDA approves Bayer's Nubeqa with ADT for metastatic hormone-sensitive prostate cancer, cutting death risk by 46%. Read more ...

Patients with metastatic castration-sensitive prostate cancer (mCSPC), who have specific genetic mutations, were found to ...

"PARP inhibitors have been a mainstay in the treatment of metastatic castration-resistant prostate cancer for patients with ...

Adding niraparib to abiraterone acetate and prednisone may help slow cancer growth for patients with metastatic ...

The approval is based on results from the phase 3 ARANOTE trial, which showed Nubeqa, when combined with androgen deprivation ...

The FDA approval is based on safety and efficacy demonstrated in the phase 3 ARANOTE trial, which evaluated darolutamide — ...

Darolutamide (Nubeqa) is granted FDA approval for metastatic castration-sensitive prostate cancer, enhancing survival and ...

The FDA has approved darolutamide without chemotherapy for treatment of metastatic hormone-sensitive prostate cancer.The FDA ...

Approval was based on results from the Phase III ARANOTE trial, in which Nubeqa demonstrated a 46% reduction in the risk of ...

Bayer has taken another step toward achieving its €3 billion peak sales estimate for androgen receptor inhibitor Nubeqa, ...

The FDA approved Nubeqa for metastatic castration-sensitive prostate cancer based on significantly improved radiographic ...

Men’s Health Month 2025 encourages men to adopt preventive care and healthy lifestyle habits to improve overall health ...